1. Which of the following correctly characterizes the duration of chronic pain?
A. Chronic pain persists 7 days or longer
B. Chronic pain persists past the expected duration of healing
C. Chronic pain persists longer than 1 month
D. Chronic pain persists longer than 1 year
2. Which of the following is a first-line nonpharmacologic treatment for acute musculoskeletal pain?
A. Acupuncture
B. Cognitive behavioral therapy
C. Chiropractic care
D. RICE (rest, ice, compression, elevation)
3. Which of the following underlies the variation in individual response to potentially toxic doses of acetaminophen?
A. Genetic variation CYP isoform expression
B. Genetic variation in sensitivity to N -acetyl-p -benzoquinoneimine (NAPQI)
C. Genetic variation in glutathione concentrations
D. Genetic variation in hepatocyte regenerative capacity
4. Which patients should receive a prescription for a proton pump inhibitor when a nonsteroidal anti-inflammatory drug (NSAID) is used for the management of acute pain?
A. All patients being treated with nonselective or COX-2–selective NSAIDs
B. High-risk patients being treated with any NSAID (non-selective or COX-2 selective)
C. High-risk patients being treated with nonselective NSAIDs
D. Patients with a history of NSAID-associated gastrointestinal bleeding
5. Which of the following is a potential advantage of topical NSAIDs compared with systemic NSAIDs?
A. Lower cost
B. Lower risk of serious adverse effects
C. Improved efficacy
D. Over-the-counter availability
6. Which of the following is NOT a first-line pharmacologic agent for the management of chronic neuropathic pain?
A. Tricyclic antidepressants (TCAs)
B. Serotonin-norepinephrine reuptake inhibitors (SNRIs)
C. Gabapentinoids
D. Topical capsaicin
7. Which of the following medication classes should be used with caution or avoided in patients with New York Heart Association class III or IV heart failure?
A. Tricyclic antidepressants
B. Serotonin-norepinephrine reuptake inhibitors
C. Gabapentinoids
D. Topical lidocaine
8. Which of the following opioids should be avoided in patients with significant renal dysfunction?
A. Oxycodone
B. Morphine
C. Fentanyl
D. Hydromorphone
9. Which of the following is NOT a strategy to mitigate the risks of opioids?
A. Use urine drug screening to check for the presence of illicit substances and/or confirm the presence of prescribed opioids
B. Avoid opioid dosages of more than 90 morphine milligram equivalents (MME) or carefully justify their use if necessary
C. Initiate therapy with long-acting or extended-release opioids
D. Coprescribe naloxone for patients at high risk of opioid overdose and/or their family members
10. Where do most patients who misuse prescription opioids obtain these drugs?
A. From friends or family members
B. From filling fraudulent prescriptions
C. From the illicit market
D. From diversion in the pharmaceutical supply chain
Evaluation Questions
11. To what extent did the program meet objective #1?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
12. To what extent did the program meet objective #2?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
13. To what extent did the program meet objective #3?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
14. To what extent did the program meet objective #4?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
15. Rate the effectiveness of how well the program related to your educational needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
16. Rate how well the active learning strategies (questions, cases, discussions) were appropriate and effective learning tools:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
17. Rate the quality of the faculty:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
18. Rate the effectiveness and the overall usefulness of the material presented:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
19. Rate the appropriateness of the examination for this activity:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
20. Rate the effectiveness of how well the activity related to your practice needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
21. Rate the effectiveness of how well the activity will help you improve patient care:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
22. Will the information presented cause you to change your practice?
A. Yes
B. No
23. Are you committed to making these changes?
A. Yes
B. No
24. As a result of this activity, did you learn something new?
A. Yes
B. No
25. What is your practice setting or area of practice?
A. Community Pharmacy/Independent
B. Community Pharmacy/Chain
C. Hospital/Health Systems
D. Administrative/Pharmacy Director
E. Critical Care Pharmacy
F. Long-term Care
G. Managed Care/PBM
H. Oncology
I. Specialty Pharmacy
J. Industry/Manufacturing
26. How many years have you been in practice?
A. <5
B. 5 – 10
C. 11 – 20
D. >20
